Iptacopan in IgA Nephropathy — Final 24-Month Data

Jonathan Barratt; Necmi Eren; Naoki Kashihara; Bart Maes; Dana V. Rizk; Brad Rovin; Hernán Trimarchi; Hong Zhang; Weiming Wang; Ismail Kocyigit; ChuanMing Hao; Vladimir Tesař; Kenan Turgutalp; Li Yang; Guangqun Xing; Valter Duro Garcia; Seung Hyeok Han; Wanhong Lu; Antonio Pisani; Julia Weinmann-Menke; Frank Eitner; Nicolas Guérard; Dmytro Butylin; Luca Monaco; Emil Scosyrev; Annabel R. Magirr; Ronny Renfurm; Thomas Hach; Vlado Perkovic

doi:10.1056/nejmoa2600743

Key Points

To evaluate the efficacy of iptacopan in slowing kidney function decline in IgA nephropathy patients.
Clinical trial comparing iptacopan therapy with placebo.
Assessment of kidney function over 24 months.
Iptacopan therapy resulted in a significantly slower decline in kidney function compared to placebo.

Implication

Clinical trial shows iptacopan slows kidney function decline compared to placebo, indicating potential benefits for patients.

Abstract

Iptacopan therapy led to a significantly slower decline in kidney function than placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Barratt et al. (2026) studied this question.

synapsesocial.com/papers/69ccb55116edfba7beb875bc https://doi.org/10.1056/nejmoa2600743

View Full Paper

Ask AI

Bookmark

Share

Iptacopan in IgA Nephropathy — Final 24-Month Data

Key Points

Implication

Abstract

Discussion

Cite This Study

Iptacopan in IgA Nephropathy — Final 24-Month Data

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading